Triggering of acute myocardial infarction by respiratory infection

Ruane, L.; Buckley, Thomas; Hoo, S. Soo; Hansen, Peter S.; McCormack, Catherine; Shaw, Elizabeth; Fethney, Judith; Tofler, Geoffrey H.

doi:10.1111/imj.13377

Cited by 33 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two other studies have evaluated the prevalence of respiratory infections and influenza among patients with angiographically confirmed MI [ 49 ] and STEMI [ 50 ], respectively. Ruane et al confirmed that respiratory infections can trigger MI [ 50 ] and Caussin et al showed that influenza epidemic may be associated with a significant excess relative risk of STEMI [ 49 ].…”

Section: Acute Coronary Syndromes and Covid-19mentioning

confidence: 99%

Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties

Schiavone

Gobbi

Biondi‐Zoccai

et al. 2020

JCM

103

View full text Add to dashboard Cite

Since an association between myocardial infarction (MI) and respiratory infections has been described for influenza viruses and other respiratory viral agents, understanding possible physiopathological links between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and acute coronary syndromes (ACS) is of the greatest importance. The initial data suggest an underestimation of ACS cases all over the world, but acute MI still represents a major cause of morbidity and mortality worldwide and should not be overshadowed during the coronavirus disease (Covid-19) pandemic. No common consensus regarding the most adequate healthcare management policy for ACS is currently available. Indeed, important differences have been reported between the measures employed to treat ACS in China during the first disease outbreak and what currently represents clinical practice across Europe and the USA. This review aims to discuss the pathophysiological links between MI, respiratory infections, and Covid-19; epidemiological data related to ACS at the time of the Covid-19 pandemic; and learnings that have emerged so far from several catheterization labs and coronary care units all over the world, in order to shed some light on the current strategies for optimal management of ACS patients with confirmed or suspected SARS-CoV-2 infection.

show abstract

Section: Acute Coronary Syndromes and Covid-19mentioning

confidence: 99%

Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties

Schiavone

Gobbi

Biondi‐Zoccai

et al. 2020

JCM

103

View full text Add to dashboard Cite

show abstract

“…Despite advances in treatments, such as antibiotic therapy and intensive care, significant improvement in mortality rates remains elusive (1) . Additionally, there is increasing awareness of the burden of cardiovascular complications in patients hospitalized with pneumonia 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 . Novel treatment strategies in this high-risk patient population are needed.…”

mentioning

confidence: 99%

Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

Sexton

Zhang

Macaulay

et al. 2018

JACC: Basic to Translational Science

111

View full text Add to dashboard Cite

show abstract

“…Whilst the occurrence of these CVEs was found to be associated with short‐term mortality , more importantly perhaps, these events have been documented to be associated with poor long‐term prognosis, as well as with raised long‐term risk of cardiovascular disease (CVD) . Cardiovascular risk following an episode of CAP has been found to be highest in the first year, or in the first few years, following hospitalization; however, the increased risk has been found to extend as far out as 10 years in those studies that have evaluated the risk over that period of time .…”

Section: Occurrence Of Cardiovascular Events In Patients With Communimentioning

confidence: 99%

Pathogenesis and prevention of risk of cardiovascular events in patients with pneumococcal community‐acquired pneumonia

et al. 2019

View full text Add to dashboard Cite

It is now well recognized that cardiovascular events (CVE) occur quite commonly, both in the acute phase and in the long‐term, in patients with community‐acquired pneumonia (CAP). CVE have been noted in up to 30% of patients hospitalized with all‐cause CAP. One systematic review and meta‐analysis of hospitalized patients with all‐cause CAP noted that the incidence rates for overall cardiac events were 17.7%, for incident heart failure were 14.1%, for acute coronary syndromes were 5.3% and for incident cardiac arrhythmias were 4.7%. In the case of pneumococcal CAP, almost 20% of patients studied had one or more of these cardiac events. Recent research has provided insights into the pathogenesis of the acute cardiac events occurring in pneumococcal infections. With respect to the former, key involvements of the major pneumococcal protein virulence factor, pneumolysin, are now well documented, whilst systemic platelet‐driven neutrophil activation may also contribute. However, events involved in the pathogenesis of the long‐term cardiovascular sequelae remain largely unexplored. Emerging evidence suggests that persistent antigenaemia may predispose to the development of a systemic pro‐inflammatory/prothrombotic phenotype underpinning the risk of future cardiovascular events. The current manuscript briefly reviews the occurrence of cardiovascular events in patients with all‐cause CAP, as well as in pneumococcal and influenza infections. It highlights the close interaction between influenza and pneumococcal pneumonia. It also includes a brief discussion of mechanisms of the acute cardiac events in CAP. However, the primary focus is on the prevalence, pathogenesis and prevention of the longer‐term cardiac sequelae of severe pneumococcal disease, particularly in the context of persistent antigenaemia and associated inflammation.

show abstract

Triggering of acute myocardial infarction by respiratory infection

Abstract: These findings confirm that respiratory infection can trigger MI. Further study is indicated to identify treatment strategies to decrease this risk, particularly in individuals who may have increased susceptibility.

Cited by 33 publications

References 38 publications

Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties

Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties

Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

Pathogenesis and prevention of risk of cardiovascular events in patients with pneumococcal community‐acquired pneumonia

Contact Info

Product

Resources

About